VINC — Vincerx Pharma Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Vincerx Pharma gains on FDA allowing human trials for its blood cancer drug
Brief: Vincerx Pharma Announces FDA Clearance Of Ind For Vip943
Vincerx Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vincerx Pharma Reposts $27.4 Mln In Cash, Cash Equivalents And Marketable Securities As Of June 30
Brief: Vincerx Pharma, Inc. Q2 Basic EPS USD -0.52
Vincerx Pharma Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Vincerx Pharma Reports First Quarter 2023 Financial Results And Provides Corporate Update
Vincerx Pharma Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Vincerx Pharma Presents Preclinical Data On Vip236, A First-In-Class Small Molecule Drug Conjugate (Smdc), At The 2023 American Association For Cancer Research (Aacr) Annual Meeting
Brief: Vincerx Pharma Reports Fourth Quarter And Full Year 2022 Financial Results And Provides A Corporate Update
Vincerx Pharma Inc reports results for the quarter ended in December - Earnings Summary
Vincerx Pharma Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Vincerx Pharma Inc Confirms That It Does Not Hold Any Deposits Or Securities Or Maintain Any Accounts At Silicon Valley Bank
Vincerx Pharma rises on FDA nod for human trials for cancer therapy
Brief: Vincerx Pharma Announces FDA Safe To Proceed Letter For Investigational New Drug Application For Its aVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
Vincerx Pharma Inc reports results for the quarter ended in September - Earnings Summary
Brief: Vincerx Pharma Inc Says Expect Cash Runway Into Late 2024 - Filing
Brief: Vincerx Pharma Reports Third Quarter 2022 Financial Results And Provides A Corporate Update
Vincerx Pharma Inc expected to post a loss of 55 cents a share - Earnings Preview